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Abstract
Tau and its aggregates are linked to the pathology of
Alzheimer’s disease (AD) and other tauopathies and, there-
fore, are explored as therapeutic targets for such disorders.
Tau belongs to a family of microtubule-associated proteins
that promote microtubule assembly. When hyperphosphory-
lated, tau becomes prone to forming aggregates. Increased
brain levels of hyperphosphorylated tau correlate with demen-
tia. Speciﬁcity protein 1 (Sp1), a transcription factor elevated in
AD, is responsible for the transcription of AD-related proteins
including the amyloid precursor protein, tau, and its cyclin-
dependent kinase-5 (CDK5) activators. Tolfenamic acid
promotes the degradation of Sp1, our previous studies
demonstrated its ability to down-regulate transcriptional
targets of Sp1 like amyloid precursor protein and reduce
amyloid beta (Ab), the main component of AD plaques. In this
study, we administered tolfenamic acid daily to hemizygous
R1.40 transgenic mice for 34 days, and examined tau and
CDK5 gene and protein expression within the brain. Our
results demonstrate that tolfenamic acid lowers tau mRNA and
protein, as well as the levels of its phosphorylated form and
CDK5. Thus, we present a drug candidate that inhibits the
transcription of multiple major intermediates in AD pathology,
thereby helping uncover a new mechanism-based approach
for targeting AD.
Keywords: Alzheimer’s disease, cyclin-dependent kinase-5,
Sp1, tau, therapy, tolfenamic acid.
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Over 100 years have passed since the identiﬁcation of
Alzheimer’s disease (AD) and no disease modifying drug has
been found for this disorder. Current therapies try to recover
the deteriorating mental functions by targeting symptoms,
but fail to alter the debilitating course of the disease that
ultimately leads to total memory loss and death. None of the
few available medications targets the characteristic patho-
logical aggregates in AD, the extracellular senile amyloid
plaques and the intracellular neuroﬁbrillary tau tangles.
The microtubule-associated protein tau was ﬁrst isolated
and recognized for its role in microtubule assembly in 1975
(Weingarten et al. 1975). In AD and other tauopathies, tau
assembles forming pathological deposits. AD is the most
common tauopathy where hyperphosphorylated tau aggre-
gates as paired helical ﬁlaments (PHFs) and tangles (Grun-
dke-Iqbal et al. 1986; Lee et al. 1991, 2001; Goedert 1997;
Brunden et al. 2009). The normal function of tau is to
stabilize microtubules, and the exact cause of its aggregation
remains unknown. Mutations in the tau gene have been
coupled with frontotemporal dementia and Parkinsonism
linked to chromosome 17 (FTDP-17) where tau aggregates
and not plaques are the characteristic deposits (Hong et al.
1998; Hutton et al. 1998; Gao et al. 2005). Tau mutations
are responsible for 5% of frontotemporal dementia cases
(Goedert and Spillantini 2011). Tau hyperphosphorylation
reduces its binding to microtubules and plays a role in its
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aggregation (Drechsel et al. 1992; Iqbal et al. 1994; Alonso
et al. 1997; Goedert 1997; Brunden et al. 2009). Hyper-
phosphorylated tau lacks its normal function of binding to
microtubules and forms neuroﬁbrillary aggregates (Beyreu-
ther and Masters 1996). Moreover, hyperphosphorylated tau
suppresses microtubules assembly and can sequester normal
tau and high molecular weight microtubule binding proteins,
restraining their normal functions (Drechsel et al. 1992;
Alonso et al. 1997; Iqbal et al. 2009, 2010; Medina 2011).
This suggests that phosphorylation regulates the functions of
tau. The main enzymes responsible for tau phosphorylation
are glycogen synthase kinase-3 beta (GSK3b) and cyclin-
dependent kinase-5 (CDK5).
Speciﬁcity protein 1 (Sp1) is a transcription factor
involved in AD pathology. Sp1 gene expression and protein
levels are elevated within the frontal cortex of AD patients
and animal models with AD-like pathology (Basha et al.
2005; Zawia and Basha 2005; Santpere et al. 2006; Brock
et al. 2008; Citron et al. 2008). Sp1 binds to GC rich
promoter regions within the amyloid precursor protein
(APP), beta-site APP cleaving enzyme 1 (BACE1), and tau
genes and promotes their transcription (Salbaum et al. 1988;
Pollwein et al. 1992; Hoffman and Chernak 1995; Heicklen-
Klein and Ginzburg 2000; Christensen et al. 2004; Docagne
et al. 2004; Gao et al. 2005; Citron et al. 2008). Sp1
regulates the expression of tau and mutations on the Sp1-
binding regions on the tau promoter decrease tau expression
(Heicklen-Klein and Ginzburg 2000; Gao et al. 2005). Sp1
protein (SP1) is co-localized with hyperphosphorylated tau in
AD tangles (Santpere et al. 2006). Sp1 also regulates the
transcription of CDK5 activators p39 and p35 with Sp1
binding motifs found on CDK5, p39, and p35 promoter
regions (Ohshima et al. 1995, 1996; Ross et al. 2002; Valin
et al. 2009). CDK5 is responsible for the phosphorylation of
tau on sites that are unusually hyperphosphorylated in AD
(Paudel et al. 1993; Ohshima et al. 1995).
Tolfenamic acid, a drug used in Europe for migraine
headaches, promotes SP1 degradation, and hence lowers the
expression of genes regulated by Sp1 including APP and
BACE1 and reduces their cleavage product amyloid beta
(Ab) (Abdelrahim et al. 2006; Adwan et al. 2011, 2014).
Tolfenamic acid also improves cognition in mice (Subaiea
et al. 2013), and is currently scheduled for a biomarker study
in AD patients. Data obtained by our collaborators demon-
strated that chronic administration of tolfenamic acid was not
toxic and had no adverse effects on animals’ weight,
hematocrit, stomach, or intestinal lining integrity compared
to control (Sankpal et al. 2013).
As lowering of hyperphosphorylated tau correlates with
cognitive improvement (Iqbal et al. 2009; O’Leary et al.
2010; Medina 2011), this study was designed to test the
ability of tolfenamic acid to down-regulate the expression of
tau and CDK5 via its unique capability to promote the
degradation of SP1 (Fig. 1). This would provide more
evidence for tolfenamic acid as a broad spectrum drug able to
interrupt multiple pathways in the neurodegenerative process
and offer more promise in its use in the upcoming clinical
studies.
Materials and methods
Chemicals and reagents
All materials used were purchased from Sigma-Aldrich (St. Louis,
MO, USA) unless otherwise indicated.
Animals
APP YAC transgenic mice, line R1.40, were used in this study (The
Jackson Laboratory, Bar Harbor, ME, USA). These animals were
particularly used to demonstrate in the same mouse model, the
ability of tolfenamic acid to impact pathways associated with both
amyloid and tau pathology. The ability of tolfenamic acid to
decrease the levels of SP1, APP and Ab and reduce BACE1 mRNA
and activity in these same animals has already been published by us,
along with behavioral tests demonstrating cognitive improvement
following tolfenamic acid treatment in these mice (Subaiea et al.
Fig. 1 Proposed transcription-based mechanism of tau and cyclin-
dependent kinase-5 (CDK5) down-regulation by tolfenamic acid.
Tolfenamic acid induces the degradation of the transcription factor
Speciﬁcity protein 1 (Sp1) (Abdelrahim et al. 2006; Adwan et al. 2011;
Subaiea et al. 2013), which reduces the transcription of its target
genes such as tau and CDK5 activators, resulting in a decrease in the
total levels of tau as well as the pathogenic phosphorylated tau
species.
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2013; Adwan et al. 2014). Animals were housed in designated
rooms within the animal facility at the University of Rhode Island.
Female hemizygous mice bred in-house were assigned into three
groups of similar age variations between 14 and 21 months of age,
n = 6 in each group. Animals were administered 0, 5, or 50 mg/kg
tolfenamic acid in corn oil everyday by oral gavage for 34 days. On
day 35, mice were killed and brain tissues were collected and stored
at 80°C until further use. The detailed information on the breeding
and exposure scenario have been already published along with the
results from the biochemical and behavioral experiments conducted
on these animals (Subaiea et al. 2013). All experiments were
performed in accordance with the standard guidelines and the
protocol approved by the Institutional Animal Care and Use
Committee of the University of Rhode Island.
RNA isolation, cDNA synthesis, and real-time PCR
RNA was isolated from cerebral cortex tissue following the
TRIzol reagent method (Invitrogen, Carlsbad, CA, USA), checked
for integrity by NanoDrop (Thermo Scientiﬁc, Wilmington, DE,
USA), and reverse transcribed to cDNA using iScriptTM Select
cDNA Synthesis Kit following manufacturer’s instructions (Bio-
Rad, Hercules, CA, USA). About 1000 ng of RNA were diluted to
19.5 lL with nuclease free water, then 3 lL Oligo (dT) mix, 6 lL
5x iScript Select reaction mix, and 1.5 lL of iScript reverse
transcriptase were added. Samples were incubated at 42°C for
90 min then at 85°C for 5 min to terminate the reaction. All
incubations were conducted using MJ Research MiniCyclerTM (Bio-
Rad). Primer pairs for mouse tau, CDK5, b-actin, and GAPDH were
obtained from Invitrogen as follows: tau sense: 50-GTGGCCAGG
TGGAAGTAAAA-30 and antisense: 50-TGGAAGACACATTGC
TGAGG-30; CDK5 sense: 50-GGCTAAAAACCGGGAAACTC-30,
and antisense: 50-CCATTGCAGCTGTCGAAATA-30; b-actin
sense: 50-TGTTACCAACTGGGACGACA-30, and antisense: 50-T
CTCAGCTGTGGTGGTGAAG-30; GAPDH sense: 50-AGCTGAA
CGGGAAGCTCACT-30, and antisense: 50-AGGTCCACCACTGA
CACGTTG-30. Each real-time PCR reaction mix contained 2 lL of
cDNA, 1 lL of each primer, 8.5 lL nuclease free water, and
12.5 lL SYBR Green PCR Master Mix (Applied Biosystems,
Foster City, CA, USA). Real time PCR was conducted using the
7500 Real Time PCR System (Applied Biosystems) following the
standard protocol: 50°C for 2 min followed by 95°C for 10 min,
then 40 cycles of 95°C for 15 s, and 60°C for 1 min. Results were
analyzed using the 7500 system software with relative quantiﬁcation
method and b-actin or GAPDH as endogenous control.
Protein extraction and western blot analyses
Cerebral cortex tissue was homogenized with radio-immunoprecip-
itation assay lysis buffer (10 mM Tris-HCl [pH 7.4], 150 mM NaCl,
1% Triton X-100, 0.1 sodium dodecyl sulfate, 1 mM ethylenedi-
aminetetraacetic acid (Thermo Fisher Scientiﬁc, Waltham, MA,
USA), and 0.1% protease inhibitor cocktail). The homogenates were
centrifuged at 10,600 g for 10 min at 4°C and supernatants were
collected. Protein concentration was determined using the Micro
BCA Protein Assay Kit (Thermo Scientiﬁc Pierce, Rockford, IL,
USA). Protein extracts were stored at 80°C until further use. For
western blot analyses, approximately 40 lg of protein samples was
separated onto 4–15% precast polyacrylamide gels (Bio-Rad) at
150 V for 1–2 h and then transferred to polyvinylidene ﬂuoride
membranes (GE-Healthcare, Piscataway, NJ, USA). Membranes
were blocked and incubated with the appropriate dilution of the
speciﬁc primary antibody for 1–2 h. The antibodies used were as
follows: 1 : 1000 dilution of T9450 for total tau levels (Sigma-
Aldrich); 1 : 1000 of CDK5 #2506 (Cell Signaling, Beverly, MA,
USA); 1 : 1000 of phosphorylated tau (P-tau) at Thr 181 #5383 (Cell
Signaling); 1 : 1000 of P-tau at Ser 235 ab30664 (Abcam, Cam-
bridge, MA, USA); 1 : 5000 of b-actin A2013 (Sigma-Aldrich); or
1 : 2000 of GAPDH T9450 (Sigma-Aldrich), then the membranes
were washed with tris-buffered saline containing 0.05% Tween 20
and incubated with the appropriate infrared dye-labeled secondary
antibody (Li-Cor, Lincoln, NE, USA) for 1 h at room temperature
(25°C) in the dark. Infrared signal of western blot bands was detected
and quantiﬁed using Odyssey Infrared Imaging System (Li-Cor).
Western blot protein levels for tau, CDK5, and P-tau were normalized
against the levels of the house keeping proteins b-actin or GAPDH.
Statistical analysis
Data were represented as the mean  SEM. Statistical analysis was
performed using GraphPad Instat software (GraphPad software, San
Diego, CA, USA) and statistical signiﬁcance was determined by
one-way ANOVA and Tukey–Kramer multiple comparisons post-test.
Results with a p-value of < 0.05 were considered statistically
signiﬁcant, and were marked with asterisks accordingly.
Results
Targeting neuroﬁbrillary tau pathology of AD by inﬂuencing
the transcription factor Sp1 is a new therapeutic approach
that can be extended to other tauopathies. Studies from our
laboratory have already provided evidence that tolfenamic
acid crosses the blood brain barrier and is able to lower SP1
and subsequently reduce APP and BACE1 transcription and
Ab levels within mice brains as well as improve cognitive
functions (Adwan et al. 2011, 2014; Subaiea et al. 2011,
2013). The safety proﬁle of tolfenamic acid has already been
established. This drug has been approved and used in Europe
for the management of migraine headaches and rheumatoid
arthritis for decades. In our experiments, we did not observe
any toxic effects on animals administered tolfenamic acid. In
this study tolfenamic acid was given daily to mice for
34 days to study the effects on tau gene expression and
protein levels. The data reported below also show the effects
of tolfenamic acid treatment on various intermediates in tau
pathology including CDK5 and P-tau at Ser 235 and Thr 181.
Tolfenamic acid lowers tau gene expression and total tau
levels in vivo
By inducing SP1 degradation and reducing its levels in these
animals (Subaiea et al. 2013), we hypothesized that tolfe-
namic acid would also reduce the gene expression of its
transcriptional targets like tau (Abdelrahim et al. 2006;
Adwan et al. 2011). Following the administration of tolfe-
namic acid to mice daily for 34 days, tau gene expression was
lowered by 48% with both the 5 and 50 mg/kg doses as
© 2014 International Society for Neurochemistry, J. Neurochem. (2015) 133, 266--272
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demonstrated by real time PCR (Fig. 2). Statistical signiﬁ-
cance was determined by one-way ANOVA [F(2, 14) = 10.287,
p = 0.0018], followed by Tukey–Kramer multiple compari-
sons post-test p < 0.001 for the control (C) versus 5 mg/kg
group, p < 0.05 for the C versus the 50 mg/kg group.
Furthermore, tolfenamic acid decreased total tau protein
levels by 46% with both doses as measured by western
blot analysis (Fig. 3). One-way ANOVA F(2,11) = 6.446,
p = 0.014. Tukey–Kramer post-test p < 0.05 for the C versus
the 5 mg/kg group and for the C versus the 50 mg/kg group.
Tolfenamic acid decreases the gene and protein expression
of CDK5 in mice
As Sp1 also regulates CDK5 activators (Valin et al. 2009),
we tested the effects of tolfenamic acid on CDK5. We found
that daily administration of tolfenamic acid to mice for a
month lowered the gene expression of CDK5 in the cerebral
cortex by about 50% (Fig. 4). One-way ANOVA F(2,
13) = 59.647, p = 2.8 9 107. Tukey–Kramer post-test
p < 0.05 for the C versus the 5 mg/kg group and for the C
versus the 50 mg/kg group. There was a lowering trend in
CDK5 levels (Fig. 5) that was not signiﬁcant when analyzed
with one-way ANOVA [F(2, 8) = 4.086, p = 0.059]. However,
when comparing the 50 mg/kg dose group to the control
group by Tukey–Kramer test, the 40% lowering in CDK5
from control was statistically signiﬁcant (p < 0.05).
Tolfenamic acid reduces the expression of phosphorylated
tau
As phosphorylation of tau affects its function and its ability
to bind to microtubules (Alonso et al. 1997, 2008; Sengupta
Fig. 2 Tau relative gene expression in cerebral cortex tissues from
mice treated with tolfenamic acid daily for 34 days. Mice were
administered 0, 5 or 50 mg/kg tolfenamic acid everyday for 34 days.
Tau mRNA levels were measured in the cerebral cortex by real time
PCR, with b-actin used as an endogenous control as mentioned in the
methods section. Values shown are for the mean  SEM, n = 6 in
each group, p = 0.018 as determined by one-way ANOVA with Tukey–
Kramer post-test *p < 0.05; **p < 0.01.
Fig. 3 Tau levels following tolfenamic acid administration. Total tau
protein levels were analyzed in the cerebral cortex following daily
administration of tolfenamic acid to transgenic mice for 34 days by
western blot analysis. Values shown are for the mean  SEM, n = 5.
Tau levels were normalized to the levels of the house keeping protein
b-actin. One-way ANOVA p = 0.014, with Tukey–Kramer post-test
*p < 0.05. Insert shows representative control (C), 5 or 50 mg/kg
treatment tau or b-actin western blot bands.
Fig. 4 Cyclin-dependent kinase-5 (CDK5) gene expression after
tolfenamic acid treatment. CDK5 mRNA levels in mice cortices were
measured with real time PCR with GAPDH as an endogenous control
as mentioned in the methods section. Values shown are for the
mean  SEM, n = 5. One-way ANOVA ***p < 0.0001 as determined by
Tukey–Kramer post-test.
Fig. 5 Cyclin-dependent kinase-5 (CDK5) levels following tolfenamic
acid treatment. CDK5 levels in cerebral cortices of mice administered
tolfenamic acid or control for 34 days were obtained by western blot
analysis. CDK5 levels were normalized to GAPDH levels. Values
shown are for the mean  SEM, n = 4. One-way ANOVA p = 0.059.
*p < 0.05 according to Tukey–Kramer post-test. Insert shows rep–
resentative control (C), 5 or 50 mg/kg treatment CDK5 or GAPDH
western blot bands.
© 2014 International Society for Neurochemistry, J. Neurochem. (2015) 133, 266--272
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et al. 1998), it was important to test how phosphorylated tau
is affected by the treatment. P-tau levels were analyzed by
western blotting using speciﬁc antibodies. P-tau at Ser 235
and P-tau at Thr 181 were lowered by both doses of
tolfenamic acid (Fig. 6 and 7). Tau phosphorylated at Ser
235 was lowered by about 15% as indicated by one-way
ANOVA [F(2, 11) = 6.105, p = 0.0165], Tukey–Kramer post-
test p < 0.05 for the C versus the 5 mg/kg group and for the
C versus the 50 mg/kg group. P-tau at Thr 181 was lowered
by about 30%, one-way ANOVA F(2, 10) = 7.272,
p = 0.0112, Tukey–Kramer post-test p < 0.05 for the C
versus the 5 mg/kg group and for the C versus the 50 mg/kg
group.
Discussion
Tolfenamic acid, a drug already available in the European
market for the management of migraine headaches, repre-
sents a novel class of drugs that could be repurposed for AD
due to its unique ability to promote the degradation of SP1
(Abdelrahim et al. 2006; Adwan et al. 2011), a transcription
factor that has been linked to AD tau and Ab pathology
(Docagne et al. 2004; Santpere et al. 2006; Brock et al.
2008; Citron et al. 2008). Previous studies from our
laboratory demonstrate that by lowering SP1, tolfenamic
acid was able to decrease the transcription of APP as well as
Ab levels in mice following 2 weeks of daily administration
(Adwan et al. 2011). Our studies show that tolfenamic acid
is readily available in the brain after dosing (Adwan et al.
2011; Subaiea et al. 2011). Behavioral and biochemical
analyses have also revealed that tolfenamic acid lowers Sp1,
APP, BACE1 mRNA and activity in addition to Ab and
improves cognition in the APP transgenic mouse model used
in this study (Subaiea et al. 2013; Adwan et al. 2014).
Drug discovery for AD has focused on targeting interme-
diates mentioned in the amyloid hypothesis of AD including
APP and Ab, and so far no successful disease-modifying
candidate has been found for this devastating disorder. Much
less attention was paid to tau which is abnormally hyper-
phosphorylated and forms aggregates in AD. More recent
studies have found a better correlation between tau and
memory impairment in AD (Medina 2011). In a transgenic
mouse model that expresses plaques and tangles, lowering
both soluble tau and Ab caused cognitive improvement,
whereas lowering only soluble Ab did not improve cognition
(Oddo et al. 2006). Tangles are later manifestations of tau
pathology and soluble phosphorylated tau is the species
responsible for neurodegenerative damage (Iqbal et al. 2009;
Medina 2011).
As cognitive impairment is better correlated with the
presence of tau and as Sp1 regulates tau expression (Heicklen-
Klein and Ginzburg 2000; Iqbal et al. 2009; Medina 2011),
we sought to study the effects of tolfenamic acid on the tau
pathology in the same animals where we observed its
cognitive beneﬁts (Subaiea et al. 2013). Data presented
within this manuscript demonstrate that tolfenamic acid
lowers tau and CDK5 levels by inhibiting their transcription.
However, the exact mechanism of action by which tolfenamic
acid enhances SP1 degradation still remains to be established.
Interestingly, we do not see much difference between the two
doses used, suggesting that to get a dose–response relation-
ship we need to go lower beyond the 5 and 50 mg/kg doses
used. Such low doses would resemble those approved for
migraine headaches management in Europe.
Tau and its abnormal phosphorylation are becoming
targets for AD therapeutics. Tau knockdown by siRNA in
vitro does not alter cell viability or the availability of
microtubules (Morris et al. 2011). Probably because other
Fig. 6 Levels of tau phosphorylated at Ser 235 after tolfenamic acid
treatment. P-tau levels were measured by western blot analysis and
normalized to GAPDH as mentioned in the methods section. Values
shown are for the mean  SEM, n = 5. One-way ANOVA p = 0.0165.
*p < 0.05 according to Tukey–Kramer post-test. Insert shows repre-
sentative C, 5 or 50 mg/kg treatment P-tau at Ser 235 or GAPDH
western blot bands.
Fig. 7 Levels of tau phosphorylated at Thr 181 following tolfenamic
acid exposure. P-tau levels were measured by western blot and
normalized to GAPDH levels. Values shown are for the mean  SEM,
n = 5. One-way ANOVA p = 0.0112. *p < 0.05 according to Tukey–
Kramer post-test. Insert shows representative C, 5 or 50 mg/kg
treatment P-tau at Thr 181 or GAPDH western blot bands.
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microtubule-associated proteins like MAP1b carry out sim-
ilar functions to tau (Morris et al. 2011). The ability of
tolfenamic acid to lower total tau levels is of great
importance (Fig. 3). It was found that lowering soluble
hyperphosphorylated tau rather than the insoluble tangles
correlates with cognitive improvement (Iqbal et al. 2009;
O’Leary et al. 2010; Medina 2011). In fact, in a neurode-
generative mouse model, tau inhibition recovered memory
function even though the buildup of tangles continued
suggesting that tangles by themselves are not responsible for
cognitive dysfunction (Santacruz et al. 2005).
It is important to note that tolfenamic acid has been used
for years, and that its interference with Sp1 should not be
alarming since it was found that Sp1 is vital during early
embryonic development only but not necessary for the
following later stages of cell growth and differentiation
(Marin et al. 1997). CDK5 is also important during nervous
system development but not crucial later in life and thus is
considered a promising target for AD where aberrant
hyperphosphorylation and aggregation of tau is a major
pathological ﬁnding (Lau et al. 2002; Piedrahita et al. 2010;
Lopez-Tobon et al. 2011).
Administration of tolfenamic acid reduced the levels of tau
phosphorylated at two sites, Ser 235 and Thr 181 (Fig. 6 and
7). Both sites are phosphorylated by CDK5 and other kinases
(Baumann et al. 1993; Liu et al. 2002). Tau phosphorylation
occurs on multiple sites and is regulated by different kinases
(Liu et al. 2006). Ser 235 was found to be one of three sites
whose phosphorylation inhibits tau binding to microtubules
(Sengupta et al. 1998). Moreover, it is one of the sites that
are especially phosphorylated in paired helical ﬁlament tau
(Morishima-Kawashima et al. 1995; Hoffmann et al. 1997).
Decreasing the levels of the tangle forming tau protein by
reducing its transcription is a novel approach for targeting
AD and other tauopathies. Data from this study demonstrate
that this can be achieved by promoting the degradation of the
transcription factor Sp1. Tolfenamic acid is able to lower tau,
CDK5, phosphorylated tau at Ser 235 and Thr 181. Hence,
tolfenamic acid represents a promising candidate that targets
both the amyloid and tau neuroﬁbrillary pathways of AD and
improves cognition through a unique transcription driven
mechanism.
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